Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its ...
Fintel reports that on July 25, 2023, Barclays maintained coverage of Ligand Pharmaceuticals, Inc. - Class B (NASDAQ:LGND) with a Overweight recommendation. As of July 6, 2023, the average one-year ...
Fintel reports that on August 23, 2023, Benchmark reiterated coverage of Ligand Pharmaceuticals, Inc. - Class B (NASDAQ:LGND) with a Buy recommendation. As of August 2, 2023, the average one-year ...
Ligand Pharmaceuticals on Tuesday completed its purchase of Pharmacopeia, and promptly cut 22 jobs at the Cranbury biotech. The downsizing represents 28 percent of Pharmacopeia's work force, the New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback